OTIC News and Press, Otonomy Inc. From 07/09/20

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a p...

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock. All shares of commo...

ObsEva Reports Positive Data from Phase 3 Uterine Fibroids Studies ObsEva SA ( OBSV ) announced positive top line data from its PRIMROSE 1 and 2 studies. PRIMROSE 1 met its primary endpoint at week 24 while PRIMROSE 2 data showed that continued treatment with linzagolix for 52 weeks offe...

Corvus Pharmaceuticals (NASDAQ: CRVS ) +103%  on launch immunotherapy study for COVID-19. More news on: Corvus Pharmaceuticals, Inc., Annovis Bio, Inc., Novavax, Inc., Stocks on the move, , Read more ...

Otonomy (NASDAQ: OTIC ) announces a positive development related to the statistical analysis plan for its ongoing Phase 3 clinical trial evaluating Otividex in patients with Ménière’s disease , a disorder of the inner ear that can lead to vertigo and hearing loss. More ...

OTO-313 demonstrated a higher proportion of responders than placebo Given clear signal in this proof of concept study, Otonomy plans to advance OTO-313 to full Phase 2 development in tinnitus OTO-313 was well-tolerated with lower incidence of adverse events than placebo group Ma...

SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on the statistical analysis plan related to the ongoing Phase 3 clinical trial of OTI...

Results from Phase 3 trial of OTIVIDEX ® in Ménière’s disease expected in first quarter of 2021 Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020 Results from Phase 1/2 trial of OTO-413 in hearing loss expected in fourth quarter o...

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a c...

SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that due to the health, safety and travel concerns of stockholders and federal, state and loca...